CJC-1295 (no DAC): GHRH analog (modified GRF 1-29)
A short-acting GHRH analog (modified GRF 1-29) that stimulates the body's own growth-hormone release — usually paired with ipamorelin; not FDA-approved.
What is CJC-1295 (no DAC)?
CJC-1295 is a modified version of the first 29 amino acids of growth-hormone-releasing hormone (GHRH) — the same active fragment as sermorelin. It prompts the pituitary to release the body's own growth hormone. The 'no-DAC' form (Modified GRF 1-29) is short-acting, favoured for mimicking natural pulsatile GH release; a separate DAC-modified form is long-acting. It is not FDA-approved and is commonly paired with ipamorelin.
Published-literature summary: A GHRH analog with a shorter half-life (~30 min) that produces pulsatile GH release closely mimicking natural physiology. Clinical research demonstrated significant increases in GH and IGF-1 levels. The no-DAC form is often preferred for maintaining natural GH pulsatility when combined with a GHRP like Ipamorelin. (Jetté et al. (2005) — J Clin Endocrinol Metab; Alba et al. (2006) — J Clin Endocrinol Metab)
How CJC-1295 (no DAC) works (mechanism)
CJC-1295 binds the GHRH receptor on the pituitary to stimulate growth-hormone and, downstream, IGF-1 secretion. In a controlled study in healthy adults, single doses raised mean GH roughly 2- to 10-fold and IGF-1 about 1.5- to 3-fold, with IGF-1 remaining elevated for up to 9–11 days for the long-acting form [1]. The no-DAC form clears quickly, which is why it's used to preserve the natural pulsatile pattern of GH release [2].
Why it's studied / reported uses
Growth hormone & IGF-1 elevation
CJC-1295 is studied for raising GH/IGF-1 and the downstream effects on body composition and recovery [1]. Robust long-term human outcome data are limited; use is largely research/community.
Dosing reported in studies
Route: subcutaneous
Short-acting GHRH analog; frequently paired with a GHRP such as Ipamorelin.
Sources: Teichman et al. (2006) — J Clin Endocrinol Metab · Ionescu & Frohman (2006) — JCEM
The no-DAC form is used to mimic natural pulsatile GH release. These figures reflect what studies or protocols reported — not a recommendation and not tailored to you.
Calculate a dose in the reconstitution calculator →Common combinations & stacks
CJC-1295 + Ipamorelin
The most common pairing combines CJC-1295 (a GHRH analog) with ipamorelin (a GH secretagogue). Acting on two complementary pathways is reported to amplify the GH pulse. This is a community protocol — not an approved or validated regimen.
Safety & side effects
CJC-1295 is not FDA-approved and human safety data are limited. Reported effects include flushing, headache, injection-site reactions and water retention. As with any agent that raises GH/IGF-1, there are theoretical concerns around blood glucose and tissue growth with sustained use; long-term safety is unknown. It is prohibited in competitive sport. Consult a licensed physician.
Studies & references
- Prolonged stimulation of GH and IGF-1 by CJC-1295, a long-acting GHRH analog, in healthy adults — PubMed 16352683 (Teichman et al., JCEM 2006)
- Growth-hormone secretagogues / GHRH analogs and body composition (review) — NCBI / PMC7108996
Frequently asked questions
Is CJC-1295 FDA-approved?
No. CJC-1295 is not FDA-approved and is generally sold as a research chemical. (Its parent GHRH fragment, sermorelin, has had approved medical forms.)
What's the difference between CJC-1295 no-DAC and with-DAC?
The no-DAC form (Modified GRF 1-29) is short-acting and used to mimic natural pulsatile GH release; the DAC form binds albumin for a much longer half-life and sustained GH/IGF-1 elevation.
How is CJC-1295 (no DAC) dosed in studies?
There is no established therapeutic human dose. Community protocols commonly cite about 100 mcg per dose, one to three times daily, often with ipamorelin (see the dosing section). This is not a recommendation.
Is CJC-1295 used with ipamorelin?
Very commonly, in community protocols — the GHRH analog and the GH secretagogue are paired to amplify a GH pulse. Neither is an approved therapy.
⚠ Research & educational use only. This page is compiled from published research and does not constitute medical advice. CJC-1295 (no DAC) is not FDA-approved and generally sold as a research chemical. Nothing here is a recommendation to use or a prescription. Safe use can only be determined by a licensed physician. Last updated 2026-07-06.